SNSE stock forecast
Our latest prediction for Sensei Biotherapeutics Inc's stock price was made on the March 2, 2022 when the stock price was at 3.28$.
In the short term (2weeks), SNSE's stock price should outperform the market by 4.16%. During that period the price should oscillate between -11.78% and +25.69%.
In the medium term (3months), SNSE's stock price should outperform the market by 5.42%. During that period the price should oscillate between -45.48% and +65.58%.Get email alerts
Create a solid portfolio with SNSE
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary bacteriophage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune system. Using the ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf cocktail approach for treating cancer patients. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. The company’s most advanced immunotherapy, SNS-301, a first-in-class ImmunoPhage™ targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell Carcinoma of the Head and Neck. Earlier stage programs include SNS-401, a ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA).
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.33$ per share.
The book value per share is -1.69$
Three months stock forecastMarch 2, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|